HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Products In Brief

This article was originally published in The Rose Sheet

Executive Summary

The “first-ever CC cream for hair” debuts, along with new lipsticks from Dr. Hauschka and skin-care offerings of a more traditional design from anti-wrinkle patch brand BIOBLISS. More new products in brief.

You may also be interested in...



Who Will Join Us? EU Regulators Seek Feedback On Proposed Clinical Trials Discussion Platform

Regulators want to know who is interested in joining their planned multi-stakeholder platform for discussions on how to improve clinical trials in Europe. They are also seeking feedback on which topics should be prioritized for discussion.

Sandoz Maintains Lead On Denosumab As It Files With FDA

Sandoz has confirmed that its denosumab biosimilar BLA has been accepted for review by the US FDA. The company – which has previously characterized its development program as a frontrunner compared to other proposed Prolia/Xgeva rivals – indicated that it was “among the first” to file.

Pipeline Watch: 11 Approvals And Eight Phase III Trial Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018553

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel